# Safety and Efficiency of γδ T Cell Against Breast Cancer(Her-, er-, and pr-)

> **NCT02418481** · PHASE1,PHASE2 · COMPLETED · sponsor: **Fuda Cancer Hospital, Guangzhou** · enrollment: 40 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **BIOLOGICAL:** DC-CIK
- **BIOLOGICAL:** γδ T Cell
- **BIOLOGICAL:** Combination

## Key facts

- **NCT ID:** NCT02418481
- **Lead sponsor:** Fuda Cancer Hospital, Guangzhou
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-04
- **Primary completion:** 2016-06
- **Final completion:** 2016-06
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2016-07-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02418481

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02418481, "Safety and Efficiency of γδ T Cell Against Breast Cancer(Her-, er-, and pr-)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02418481. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*